| GRYGÁRKOVÁ, I., V. KOLEK, Jana SKŘIČKOVÁ, M. PEŠEK, P. ZATLOUKAL, F. SALAJKA, J. ROUBEC, D. SIXTOVÁ, L. KOUBKOVÁ a Karel HEJDUK. Group of patients with NSCLC treated with erlotinib in the Czech Republic longer than 12 months. In 13th Central European Lung Cancer Conference. 2012. ISSN 0169-5002. Dostupné z: https://dx.doi.org/10.1016/j.lungcan.2012.05.057. |
Další formáty:
BibTeX
LaTeX
RIS
@proceedings{989257,
author = {Grygárková, I. and Kolek, V. and Skřičková, Jana and Pešek, M. and Zatloukal, P. and Salajka, F. and Roubec, J. and Sixtová, D. and Koubková, L. and Hejduk, Karel},
booktitle = {13th Central European Lung Cancer Conference},
doi = {http://dx.doi.org/10.1016/j.lungcan.2012.05.057},
keywords = {lung cancer; erlotinib},
language = {eng},
title = {Group of patients with NSCLC treated with erlotinib in the Czech Republic longer than 12 months},
year = {2012}
}
TY - CONF
ID - 989257
AU - Grygárková, I. - Kolek, V. - Skřičková, Jana - Pešek, M. - Zatloukal, P. - Salajka, F. - Roubec, J. - Sixtová, D. - Koubková, L. - Hejduk, Karel
PY - 2012
TI - Group of patients with NSCLC treated with erlotinib in the Czech Republic longer than 12 months
KW - lung cancer
KW - erlotinib
N2 - Targeted biological therapy with inhibitors of tyrosine kinases is one of the therapeutic modality therapies of advanced stage non-small cell lung cancer (NSCLC). These drugs block activation cascade of epidermal growth factor receptor (EGFR). The sensitivity of tumor cells to tyrosine kinase inhibitors increases the “activating” mutations of tyrosine kinase domain and, especially, deletion in exon 19 or point mutation in exon 21.
ER -
GRYGÁRKOVÁ, I., V. KOLEK, Jana SKŘIČKOVÁ, M. PEŠEK, P. ZATLOUKAL, F. SALAJKA, J. ROUBEC, D. SIXTOVÁ, L. KOUBKOVÁ a Karel HEJDUK. Group of patients with NSCLC treated with erlotinib in the Czech Republic longer than 12 months. In \textit{13th Central European Lung Cancer Conference}. 2012. ISSN~0169-5002. Dostupné z: https://dx.doi.org/10.1016/j.lungcan.2012.05.057.
|
